Corvalol’s sales in Russia declined to the lowest levels seen since 2018 by the close of 2023, according to DSM Group. The agency notes a waning demand for the remedy among Russians, a trend reported by the publication Vedomosti.
In the 12 months of January through December, about 40 million packs of Corvalol were sold within the country, marking a 7% decrease from 2022 when 43 million packs moved through outlets.
The downward trajectory of Corvalol sales stretches over several years. In 2021, pharmacists recorded 46 million packs purchased from Russian pharmacies, and the year 2020 saw 50 million packs sold. This pattern indicates a steady softening of demand for the product in recent times.
Corvalol originated in the Soviet era during the 1960s as a domestic analogue to the German preparation Valocordin. The medication has been used to alleviate anxiety and promote a sense of calm in various consumer settings.
Analysts noted in January a sharp decline in the availability of inexpensive medications within the Russian market, highlighting a broader challenge for affordability and access to low-cost therapeutics.
Earlier reports discussed the disappearing supply of psychotropic drugs from Russian pharmacies, a development of concern for patients relying on such products for symptom relief.
There were also discussions about policy considerations by the Ministry of Finance regarding the potential introduction of a special consumption tax on medicinal alcohol, which could influence pricing and patient access to alcohol-containing remedies like Corvalol.